Last year, South Korean biotech firm SolGent made diagnostic kits for 300,000 tests. SolGent, which is one of the five firms that have received fast-track approval to make test kits for South Korea, is capitalizing on the country's success in containing its outbreak to boost exports, with cases slowing down at home. SolGent has even got offers from three U.S. biotech firms to license its technology so that they can manufacture test kits in the United States, You said, adding nothing has been decided.